Method for increasing expression of recombinant protein in escherichia coli through decoupling
By integrating the phage Gp2 and Gp5.7 genes in E. coli and controlling expression using T7RNA polymerase and phosphorus attenuation promoter, the decoupling of protein production in E. coli is achieved, and the difficulty of regulating protein expression in the prior art is solved. The problem of low productivity significantly increases the expression and yield of proteins.
Patent Information
- Application Number
- CN202410915144.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-09
- Publication Date
- 2024-11-08
AI Technical Summary
When the prior art regulates the expression of heterologous genes in E. coli, it is difficult to achieve precise regulation of protein expression levels without affecting cell growth, resulting in unbalanced resource allocation and low productivity.
By integrating the Gp2 and Gp5.7 genes of the bacteriophage into the genome of E. coli, T7RNA polymerase and phosphorus attenuation promoter control gene expression, the decoupling of bacterial growth and protein production is achieved, and the expression of the target protein is induced by IPTG.
The expression of fluorescent protein RFP was significantly improved, and the yield reached 3.85 times that of BWY01, proving that this method can improve protein production efficiency without affecting cell growth.
Smart Images

Figure CN118909896A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms, and in particular relates to a method for increasing the expression of recombinant proteins in Escherichia coli through decoupling. Background Art
[0002] In Escherichia coli, the relationship between cell proliferation rate and gene expression level profoundly affects the efficiency and sustainability of biotechnology and industrial production. High-level expression of heterologous genes is a key step in many biomanufacturing processes. It not only determines the yield of target proteins, but also directly affects the physiological state and growth performance of host cells. High-level expression of heterologous genes can cause bacteria to over-consume metabolic resources, such as nucleotides, amino acids, and energy substances, resulting in an imbalance in resource allocation and greater metabolic growth pressure on bacteria.
[0003] To overcome this problem, researchers have developed a variety of strategies to regulate the expression of heterologous genes to optimize the production of recombinant proteins. Current technologies include regulating the transcriptional activity of target genes by changing culture conditions (such as temperature, pH, etc.), optimizing the strength of promoters, or using specific inducers. In addition, precise control of protein expression can also be achieved by engineering host cells, such as constructing specific mutants or manipulating metabolic pathways. However, most of the existing technologies achieve high expression by restricting cell growth, which sacrifices productivity and efficiency in the biomanufacturing process to a certain extent. In addition, these methods are usually difficult to achieve precise regulation of protein expression levels without affecting the health of cells, thereby limiting the flexibility and controllability of host cells in different applications.
[0004] Therefore, there is a lack of an ideal system that can regulate the expression rate at the cellular level and decouple cell growth from target protein production. Summary of the invention
[0005] The purpose of this section is to summarize some aspects of embodiments of the present invention and briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section and the specification abstract and the invention title of this application to avoid blurring the purpose of this section, the specification abstract and the invention title, and such simplifications or omissions cannot be used to limit the scope of the present invention.
[0006] In view of the above problems and / or the problems existing in the prior art, the present invention is proposed.
[0007] Therefore, the object of the present invention is to overcome the deficiencies in the prior art and provide a host cell.
[0008] To solve the above technical problems, the present invention provides the following technical solution: a host cell, comprising one or more of the following (A1) to (A3):
[0009] (A1) comprises, under the control of a promoter, nucleotide sequences encoding two proteins from a bacteriophage that inhibit the growth of said bacterial host cell, wherein the growth is inhibited by inhibiting transcription;
[0010] (A2) comprises a nucleotide sequence encoding an RNA polymerase that is heterologous to the bacterial host cell, wherein the RNA polymerase is T7 bacteriophage RNA polymerase;
[0011] (A3) comprising a nucleotide sequence encoding a target protein under the control of a promoter recognized by the RNA polymerase,
[0012] The nucleotide sequence encoding two proteins from bacteriophage that inhibit the growth of the bacterial host cell and the nucleotide sequence encoding the RNA polymerase are integrated into the genome of the host cell, and the proteins from bacteriophage that inhibit the growth of the bacterial host cell are proteins that inhibit the RNA polymerase of the bacterial host cell, the two proteins that inhibit the growth of the bacterial host cell are Gp2 and Gp5.7, the amino acid sequence of Gp2 is shown in SEQ ID NO.4, and the amino acid sequence of Gp5.7 is shown in SEQ ID NO.5.
[0013] As a preferred embodiment of the host cell of the present invention, the nucleotide sequence encoding the Gp2 and Gp5.7 target proteins is integrated into the genome of the host cell.
[0014] As a preferred embodiment of the host cell of the present invention, the integration site of the gene encoding Gp2 and Gp5.7 proteins is the 186KO_S site of the Escherichia coli BW25113 genome.
[0015] As a preferred embodiment of the host cell of the present invention, the promoter is a phospho-attenuation promoter.
[0016] Another object of the present invention is to overcome the deficiencies in the prior art and provide a preparation containing the host cell, comprising the following (A1) or (A2):
[0017] (A1) comprising a nucleotide sequence encoding a protein derived from a bacteriophage as defined in claim 1 that inhibits the growth of said bacterial host cell under the control of a promoter;
[0018] (A2) comprises a nucleotide sequence encoding an RNA polymerase that is heterologous to the bacterial host cell, wherein the RNA polymerase is T7 bacteriophage RNA polymerase,
[0019] The nucleotide sequence encoding the protein from bacteriophage that inhibits the growth of the bacterial host cell and the nucleotide sequence encoding the RNA polymerase are integrated into the genome of the host cell.
[0020] Another object of the present invention is to overcome the deficiencies in the prior art and provide a method for producing a recombinant protein, comprising culturing the host cell under the conditions of pH = 7.0 and 20° C. and obtaining the recombinant protein.
[0021] Another object of the present invention is to overcome the deficiencies in the prior art and provide a method for producing a recombinant protein, comprising contacting the preparation with a nucleic acid molecule under the conditions of pH = 7.0 and 20°C, wherein the nucleic acid molecule comprises a nucleotide sequence encoding a target protein under the control of a promoter recognized by a defined RNA polymerase.
[0022] Another object of the present invention is to overcome the deficiencies in the prior art and provide a method for increasing the expression of recombinant proteins in Escherichia coli by decoupling, comprising culturing the defined bacterial host cells under conditions of pH = 7.0 and 20°C and obtaining the target protein.
[0023] Another object of the present invention is to overcome the deficiencies in the prior art and provide a use of the host cell or the preparation in producing recombinant proteins.
[0024] Another object of the present invention is to overcome the deficiencies in the prior art and provide a use of the host cell or the preparation in increasing the yield of recombinant protein.
[0025] Beneficial effects of the present invention:
[0026] The present invention integrates a 1 gene expressing T7 RNA polymerase at the 186KO_P site of the genome of Escherichia coli BW25113, and integrates 2 genes and 5.7 genes from T7 phage at the 186KO_S site of the genome of Escherichia coli BW25113, uses a phosphorus attenuation promoter to control the expression of 2 genes and 5.7 genes, and uses IPTG to induce the expression of the target recombinant protein. Taking the fluorescent protein RFP as an example, after shake flask fermentation, the expression amount of the fluorescent protein RFP in the strain BWY04 integrated with 2 genes + 5.7 genes is 3.2 times that of BWY01. After fermentation tank amplification culture, the yield of RFP in BWY04 can reach 5.4g / L, and the yield of RFP BWY01 is 1.4g / L. It is calculated that the yield of RFP in BWY04 is 3.85 times that of BWY01. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for describing the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor. Among them:
[0028] Figure 1 This is a technical schematic diagram of a decoupling system in Embodiment 1 of the present invention;
[0029] Figure 2 This is an agarose gel electrophoresis analysis diagram in Example 1 of the present invention;
[0030] Figure 3 This is an agarose gel electrophoresis analysis diagram in Example 2 of the present invention;
[0031] Figure 4 This is a plate image of the resistance fragment verified in Example 2 of the present invention;
[0032] Figure 5 The SDS-PAGE analysis of the expression of RFP in 4 strains in Example 2 of the present invention;
[0033]
[0034] Figure 6 is the expression level of RFP in four strains in Example 3 of the present invention;
[0035] Figure 7 This is a diagram of RFP protein purification in Example 5 of the present invention;
[0036] Figure 8 This is a comparison chart of RFP protein yield in Example 5 of the present invention. DETAILED DESCRIPTION
[0037] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with the embodiments of the specification.
[0038] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein, and those skilled in the art may make similar generalizations without violating the connotation of the present invention, so the present invention is not limited to the specific embodiments disclosed below. Secondly, the "one embodiment" or "embodiment" referred to herein refers to a specific feature, structure or characteristic that may be included in at least one implementation of the present invention. The "in one embodiment" that appears in different places in this specification does not all refer to the same embodiment, nor is it a separate or selective embodiment that is mutually exclusive with other embodiments.
[0039] The raw materials and reagents used in the present invention are shown in Table 1:
[0040] Table 1
[0041]
[0042]
[0043] Formula of fermentation medium: glycerol (60ml / L), trypsin hydrolyzate (10g / L), yeast extract (5g / L), potassium dihydrogen phosphate (3.4g / L), 9Na2HPO4·12H2O (9g / L), NH4Cl (2.7g / L), Na2SO4 (0.7g / L), defoamer (1ml / L). Add 50mL 20× metal ion storage solution, 20mL 50% glucose, 1mL 500g / LMgSO4·7H2O before use and mix well.
[0044] Formula of metal ion storage solution: take 2016 mg ferric citrate, 50 mg cobalt chloride hexahydrate, 300 mg MnCl2.4H2O, 30 mg CuCl2.2H2O, 60 mg boric acid, 42 mg sodium molybdate, 616 mg zinc acetate anhydrous, 282 mg EDTA, add ultrapure water to dissolve, dilute to 1 L, and filter to remove impurities.
[0045] Unless otherwise stated, the experimental methods disclosed in the present invention all adopt conventional techniques in molecular biology and related fields in the art.
[0046] Example 1
[0047] 1. Integrate the 1 gene (nucleotide sequence as shown in SEQ ID NO.1) expressing T7 RNA polymerase into the 186KO_P site of the E. coli BW25113 genome, integrate the 2 gene (nucleotide sequence as shown in SEQ ID NO.2) and the 5.7 gene (nucleotide sequence as shown in SEQ ID NO.3) expressing the T7 phage regulatory protein into the 186KO_S site of the E. coli BW25113 genome, and use the phosphorus attenuation promoter to control the expression of the 2 gene and the 5.7 gene, so that the Gp2 protein (amino acid sequence as shown in SEQ ID NO.4) and the Gp5.7 protein (amino acid sequence as shown in SEQ ID NO.5) act on the host RNA polymerase to inhibit the replication and expression of the host's own genes, thereby inhibiting the division of the host cells. After the host growth is inhibited, the T7 promoter is used to control the transcription of the target protein. Based on the above two-step strategy, the decoupling of bacterial growth and target protein production is achieved during the expression of recombinant proteins, and metabolic resources can be used exclusively for transcription and translation into the final target protein. The technical principle diagram is shown in the figure below. Figure 1 shown.
[0048] Gene 1 was integrated into the BW25113 genome, and the integrated strain was named BWY01. Gene 2, gene 5.7, and gene 2 + gene 5.7 were integrated into the BWY01 genome, and they were named BWY02, BWY03, and BWY04, respectively. BWY01 without phage gene integration was used as a negative control to induce the expression of RFP protein. Here, BWY04 is used as an example to illustrate the process of strain construction:
[0049] The fragment containing gene 1 synthesized by GenScript was used as a template, LC877 (nucleotide sequence as shown in SEQ ID NO.6) and LC871 (nucleotide sequence as shown in SEQ ID NO.7) were used as primers, and the target fragment 1 gene was obtained by PCR. The pOSIP_KO (Addgene: 45985) plasmid was digested according to the following table, and the digestion system was shown in Table 2. The backbone fragment was obtained after gel recovery, and the above two fragments were recombined to obtain the target pOSIP plasmid containing gene 1. The pOSIP plasmid containing gene 1 was transformed into Escherichia coli BW25113 competent cells and plated on LBAgar plates containing 20 μL / mL of kanamycin for overnight culture.
[0050] Table 2
[0051]
[0052] Example 2
[0053] Using P1_LC822 (nucleotide sequence as shown in SEQ ID NO.8), P2_LC819 (nucleotide sequence as shown in SEQ ID NO.9), P3_LC820 (nucleotide sequence as shown in SEQ ID NO.10), and P4_LC823 (nucleotide sequence as shown in SEQ ID NO.11) as primers, 4 monoclonal clones on the plate were randomly selected as templates for PCR verification. The expected PCR product size is shown in Table 3. The results of agarose gel electrophoresis analysis are shown in Table 3. Figure 2 The fragment sizes of the target products are shown in Table 3, which are 389 bp and 328 bp, verifying that they are positive clones integrated into the P site, and then prepared into DWY01_186KO_P competent cells.
[0054] The pE-FLP (Addgene: 45978) plasmid was transformed into the above DWY01_186KO_P competent cells and plated on LBAgar solid medium containing ampicillin for overnight culture. The host strain carrying the pE-FLP plasmid was propagated at 30°C, and FLP-mediated excision occurred at night when the colony grew. At higher temperatures, the replication of the plasmid will stop, and it will be diluted and lost as the cells divide.
[0055] To check the successful removal of the integrated module, the isolated single colonies were re-strung onto three different plates in the following order: LB kanamycin (20 μg / mL) plate, LBAgar ampicillin (100 μg / mL) plate, and LBAgar (without antibiotics) plate. The three plates were incubated at 42°C for 2 h and then moved to a 37°C incubator for overnight growth. The strain containing the 1 gene after losing the kanamycin resistance fragment was named BWY01.
[0056] Using the fragment containing 2 genes + 5.7 genes synthesized by GenScript as a template, LC859 (nucleotide sequence as shown in SEQ ID NO.12) and LC874 (nucleotide sequence as shown in SEQ ID NO.13) as primers, PCR obtained the target fragment 2 genes + 5.7 genes, and the expected PCR product size is shown in Table 4. It was recombined with the pOSIP plasmid backbone fragment obtained by enzyme cutting to obtain a pOSIP plasmid containing 2 genes + 5.7 genes (nucleotide sequence as shown in SEQ ID NO.14), which was transferred to BWY01 and spread on a 20 μL LB agar plate containing kanamycin for overnight culture. Positive clones were selected using primers P5_LC824 (nucleotide sequence as shown in SEQ ID NO.15), P2_LC819, P3_LC820, and P6_LC825 (nucleotide sequence as shown in SEQ ID NO.16). It was prepared into competent cells, transferred into pE-FLP plasmid to remove the resistance fragment and verify whether it was removed. The results are as shown in Figure 3 As shown, the strain with resistance removed and containing the pOSIP plasmid of 2 genes + 5.7 genes was named BWY04. The fragment sizes of the target products are shown in Table 4, which are 648 bp and 429 bp, verifying that it is a positive clone integrated in the P site.
[0057] In the same way, the pOSIP plasmid containing the 2 gene was transferred into BWY01, and after resistance loss using the pE-FLP plasmid, the strain was named BWY02; the pOSIP plasmid containing the 5.7 gene was transferred into BWY01, and after resistance loss, the strain was named BWY03.
[0058] Table 3
[0059]
[0060] Table 4
[0061]
[0062] Example 3 Testing the decoupling system of Escherichia coli growth and production
[0063] The fluorescent protein RFP was transferred into BWY01, BWY02, BWY03, and BWY04 competent cells. After plating, a single clone was picked and cultured overnight in 3 mL of LB containing AMP antibiotics. After amplification and culture with S2 medium for about 8 hours, IPTG (isopropyl-β-D-thiogalactoside) was added at a final concentration of 0.5 mM to induce RFP protein expression. The formula of the medium S2 used was: take 20.9 g Bis-Tris, 2.7 g ammonium sulfate, 1.75 g casamino acids, 1.5 mL HCl, 3.1 g Yeast Extract, dissolve in ultrapure water, make up to 500 mL, and sterilize.
[0064] The cells were collected at OD*V=13.75, and SDS-PAGE analysis was performed after lysis. The results of gel analysis were as follows: Figure 5 shown.
[0065] The expression levels of RFP in the four strains were as follows Figure 6 As shown, the results showed that the expression level of RFP in BWY02 was about 1.5 times that of BWY01, the expression level of RFP in BWY03 was about 1.2 times that of BWY01, and the expression level of RFP in BWY04 was about 3.2 times that of BWY01.
[0066] Example 4 Fermentation of BWY01 RFP and BWY04 RFP
[0067] The present invention is based on the RFP protein and describes the fermentation process of expressing the plasmid in BWY01 and BWY04 Escherichia coli.
[0068] On the first day, the constructed and sequenced RFP plasmid was transfected into the modified strains BWY01 and BWY04. A single clone was picked from the LB Agar plate on the second day and diluted on another LB Agar plate in order to pick a single clone.
[0069] On the next day, a single clone was selected for 3 ml culture and cultured overnight at 37°C and 180 rpm.
[0070] On the third day, when the OD600 of the overnight culture reached about 4, 3 ml of the overnight culture was added to the fermentation tank containing 300 ml of fermentation medium.
[0071] According to the formula of the fermentation broth, it is directly prepared in a 1L fermenter (antibiotics, defoamers and trace metal element storage solutions are not added temporarily), the outlet and inlet filters of the fermenter are closed, and sterilized in an autoclave. After sterilization, a sterile stock solution of ampicillin (100 mg / ml), a defoamer and a metal element storage solution are added respectively. The pH value is adjusted to 7.0 with 25% NaOH. The oxygenation level is set to 25% and controlled by a constant stirrer speed (200-800 rpm).
[0072] On the third day of inoculation, the reactor temperature was set to 25°C. When OD600 was about 50, the temperature was set to 20°C, and IPTG (0.8 mM) was added to induce protein expression. In the exponential feeding phase, a medium containing 70% glucose was used for exponential feeding. When the oxygenation level suddenly increased and the carbon source was exhausted, the fermenter was set for exponential feeding.
[0073] About 30 hours after IPTG induction, stop the fermentation. Collect the cells by centrifugation at 4200g and remove the culture medium. Add 200ml of cell suspension (20mM Tris-HCl) and resuspend the cells at 4℃ (about 58g dry weight cells). Store the resuspended cells at -20℃ for the next step. Based on this fermentation method, about 5.4g / L of RFP can be obtained.
[0074] Example 5 Purification of RFP protein
[0075] In this example, the N-terminus of RFP has a His tag, thereby facilitating protein purification.
[0076] Specific RFP extraction process:
[0077] First, the cell suspension stored at -20°C was thawed and centrifuged (4000 g, 10 minutes), then the supernatant was removed, resuspended in lysis buffer to a volume of 50 ml, and Universal BenzoNuclease was added to 10 U / ml.
[0078] The cells were then lysed by ultrasound, and the ultrasound conditions were: 4°C, 400W, 4 seconds, 6 seconds, 60 cycles, and the lysed cells were centrifuged at 15000g for 45 minutes at 4°C to remove insoluble debris. The supernatant after ultrasound was transferred to a new centrifuge tube, and the supernatant was filtered with a 0.45μM syringe filter to remove insoluble particles. The filtered cell lysis supernatant was loaded onto a Ni-NTA column at 4°C by an AKTAExplorer liquid chromatography system.
[0079] Secondly, the filtered lysate was loaded onto a Ni-NTA column. After the lysate was loaded, the column was washed with a buffer solution 4 times the volume of the lysate, and then with a buffer solution containing 1 mM imidazole (4 times the volume of the lysate, the lysate is shown in Table 5).
[0080] Finally, the protein was eluted with 250 mM imidazole (0.5 times the volume of lysate). The entire system was set to flow at a rate of 3 ml / min. Figure 7 This is a gel image of the purified RFP analyzed by SDS-PAGE.
[0081] RFP protein yield Figure 8 As shown, the yield of BWY04RFP can reach 5.4g / L, and the yield of BWY01RFP is 1.4g / L. It is calculated that the yield of BWY04RFP is 3.85 times that of BWY01.
[0082] Table 5
[0083]
[0084] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solutions of the present invention, which should all be included in the scope of the claims of the present invention.
[0085] synthetic construct
[0086] Sequence Listing
[0087] SEQ ID NO.1
[0088] Artificial sequence
[0089] SEQ ID NO.1
[0090]
[0091] SEQ ID NO.2
[0092] TCAAACGTAAATACAGGTTCACTTAGTGTGGACAATAAGAAGTTTTGGGCTACCGTAGAGTCCTCGGAGCATTCCTTCGAGGTTCCAATCTACGCTGAGACCCTAGACGAAGCTCTGGAGTTAGCCGAATGGCAATACGTTCCGGCTGGCTTTGAGGTTACTCGTGTGCGTCCTTGTGTAGCACCGAAG
[0093] SEQ ID NO.3
[0094] TCTGACTACCTGAAAGTGCTGCAAGCAATCAAAAGTTGCCCTAAGACTTTCCAGTCCAACTATGTACGGAACAATGCGAGCCTCGTAGCGGAGGCCGCTTCCCGTGGTCACATCTCGTGCCTGACTACTAGTGGACGTAACGGTGGCGCTTGGGAAATCACTGCTTCCGGTACTCGCTTTCTGAAACGAATGGGAGGATGTGTC
[0095] SEQ ID NO.4
[0096] SNVNTGSLSVDNKKFWATVESSEHSFEVPIYAETLDEALELAEWQYVPAGFEVTRVRPCVAPK
[0097] SEQ ID NO.5
[0098] SDYLKVLQAIKSCPKTFQSNYVRNNASLVAEAASRGHISCLTTSGRNGGAWEITASGTRFLKRMGGCV
[0099] SEQ ID NO.6
[0100] GGGGATCGGAATTCGAGCTCGGTACCCGGGCGCAACTCGTGAAAGGTAGG
[0101] SEQ ID NO.7
[0102] AGGCGCCATGCATCTCGAGGCATGCCTGCATTACGCGAACGCGAAGTCC
[0103] SEQ ID NO.8
[0104] CTCATTCGAAACCACCCACCG
[0105] SEQ ID NO.9
[0106] ACTTAACGGCTGACATGG
[0107] SEQ ID NO.10
[0108] ACGAGTATCGAGATGGCA
[0109] SEQ ID NO.11
[0110] GATCATCATGTTTATTGCGTGG
[0111] SEQ ID NO.12
[0112] AGGCGCCATGCATCTCGAGGCATGCCTGCAATGCTAGTTATTGCTCAGC
[0113] SEQ ID NO.13
[0114] GGGGATCGGAATTCGAGCTCGGTACCCGGGCGATTCATTAATGCGTGCG
[0115] SEQ ID NO.14
[0116]
[0117] SEQ ID NO.15
[0118] TCCGGAATGCCTGCATTG
[0119] SEQ ID NO.16
[0120] CCCTGGAGCCAAAATATCC
Claims
1. A host cell, characterized in that: The host cell is Escherichia coli, including one or more of the following (A1) to (A3): (A1) comprises, under the control of a promoter, nucleotide sequences encoding two proteins from a bacteriophage that inhibit the growth of said bacterial host cell, wherein the growth is inhibited by inhibiting transcription; (A2) comprises a nucleotide sequence encoding an RNA polymerase that is heterologous to the bacterial host cell, wherein the RNA polymerase is T7 bacteriophage RNA polymerase; (A3) comprising a nucleotide sequence encoding a target protein under the control of a promoter recognized by the RNA polymerase, The nucleotide sequence encoding two proteins from bacteriophage that inhibit the growth of the bacterial host cell and the nucleotide sequence encoding the RNA polymerase are integrated into the genome of the host cell, and the proteins from bacteriophage that inhibit the growth of the bacterial host cell are proteins that inhibit the RNA polymerase of the bacterial host cell, the two proteins that inhibit the growth of the bacterial host cell are Gp2 and Gp5.7, the amino acid sequence of Gp2 is shown in SEQ ID NO.4, and the amino acid sequence of Gp5.7 is shown in SEQ ID NO.
5.
2. The host cell according to claim 1, characterized in that: The nucleotide sequences encoding the Gp2 and Gp5.7 target proteins are integrated into the genome of the host cell.
3. The host cell according to claim 2, characterized in that: The integration site of the gene encoding Gp2 and Gp5.7 proteins is the 186KO_S site of the Escherichia coli BW25113 genome.
4. The host cell according to claim 1, characterized in that: The promoter is a phospho-attenuated promoter.
5. A preparation containing the host cell according to claim 1, characterized in that: Includes the following (A1) or (A2): (A1) comprising a nucleotide sequence encoding a protein derived from a bacteriophage as defined in claim 1 that inhibits the growth of said bacterial host cell under the control of a promoter; (A2) comprises a nucleotide sequence encoding an RNA polymerase that is heterologous to the bacterial host cell, wherein the RNA polymerase is T7 bacteriophage RNA polymerase, The nucleotide sequence encoding the protein from bacteriophage that inhibits the growth of the bacterial host cell and the nucleotide sequence encoding the RNA polymerase are integrated into the genome of the host cell.
6. A method for producing a recombinant protein, characterized in that: The host cell according to any one of claims 1 to 4 is cultured under the conditions of pH = 7.0 and 20°C to obtain the recombinant protein.
7. A method for producing a recombinant protein, characterized in that: The preparation according to claim 5 is contacted with a nucleic acid molecule comprising a nucleotide sequence encoding a target protein under the control of a promoter recognized by an RNA polymerase as defined in claim 5 at pH 7.0 and 20°C.
8. A method for increasing the expression of a recombinant protein in Escherichia coli by decoupling, characterized in that: Cultivate the bacterial host cell defined in any one of claims 1 to 4 under the conditions of pH = 7.0 and 20°C and obtain the target protein.
9. Use of the host cell according to any one of claims 1 to 4 or the preparation according to claim 5 in producing a recombinant protein.
10. Use of the host cell according to any one of claims 1 to 4 or the preparation according to claim 5 in increasing the yield of a recombinant protein.
